Personalized Stem Cells, Inc. Proceeds with Stem Cell Trial for Knee Osteoarthritis – EIN News

Personalized Stem Cells, Inc. proceeds with FDA approved stem cell trial for knee osteoarthritis with new safety precautions amid COVID-19 pandemic.

POWAY, CALIFORNIA, US, May 26, 2020 / — Personalized Stem Cells, Inc (PSC), a human adipose-derived stem cell company, has continued enrollment for participation in an FDA approved clinical trial for stem cell treatment of knee osteoarthritis. Though the trial never stopped, in-person visits were halted, and telemedicine was employed per the new FDA guidelines. New safety measures have been put in place by the doctors to meet the FDA’s recommendations to slow the transmission of the virus so the in-person visits may now resume.

The clinical trial, which was launched in September 2019, is studying the effects of autologous, adipose-derived stem cell therapy for knee osteoarthritis. Patients who were enrolled prior to the enactment of various nationwide stay-at-home orders continued to receive follow-up care from their physicians through phone calls or video conferences. With new social distancing measures in place, clinical trial investigators have resumed enrolling qualified patients for participation in the clinical trial. At this time, all